Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857362 | 0.89 | AOC3 (0.46) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25833514 | 0.85 | AOC3 (0.48) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25303921 | 0.84 | AOC3 (0.47) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25832945 | 0.83 | SLC6A2 (0.52) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25299653 | 0.83 | AOC3 (0.46) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL31068695 | 0.83 | AOC3 (0.46) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25857357 | 0.82 | AOC3 (0.45) | AOC3GBA1SLC6A4SLC6A2TAAR1 | |
| SCHEMBL25857406 | 0.80 | AOC3 (0.43) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25833396 | 0.80 | AOC3 (0.43) | AOC3GBA1SLC6A4SLC6A2TSHR | |
| SCHEMBL25833427 | 0.79 | AOC3 (0.49) | AOC3GBA1SLC6A4SLC6A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | AOC3 3111/4885GBA1 4295/4885SLC6A4 2807/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | AOC3 3111/4885GBA1 4295/4885SLC6A4 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.